Fulcrum Therapeutics Inc. (FULC)
$3.85
$0.01
(0.26%)
As on 04-Sep-2026 13:36EDT
Market cap
$294 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
76,297,257
7 Years Aggregate
CFO
$-402.27 Mln
EBITDA
$-504.57 Mln
Net Profit
$-484.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fulcrum Therapeutics (FULC)
| -66.0 | 3.8 | 19.6 | -41.0 | -12.4 | -32.8 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Fulcrum Therapeutics (FULC)
| 140.6 | -30.2 | -7.3 | -58.8 | 51.1 | -29.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fulcrum Therapeutics (FULC)
|
3.9 | 293.7 | 0.0 | -85.0 | -- | -25.8 | -- | 0.9 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage... product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read more
-
CEO, President & Director
Mr. Alexander C. Sapir
-
CEO, President & Director
Mr. Alexander C. Sapir
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Fulcrum Therapeutics (FULC)
What is the current share price of Fulcrum Therapeutics Inc (FULC) Today?
The share price of Fulcrum Therapeutics Inc (FULC) is $3.85 (NASDAQ) as of 04-Sep-2026 13:36 EDT. Fulcrum Therapeutics Inc (FULC) has given a return of -12.36% in the last 3 years.
What is the current PB & PE ratio of Fulcrum Therapeutics Inc (FULC)?
Since, TTM earnings of Fulcrum Therapeutics Inc (FULC) is negative, P/E ratio is not available.
The P/B ratio of Fulcrum Therapeutics Inc (FULC) is 0.95 times as on 28-Aug-2026, a 82 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-9.57 |
2.05 |
2024 |
-26.08 |
1.04 |
2023 |
-4.29 |
1.78 |
2022 |
-3.45 |
1.91 |
2021 |
-9.16 |
3.39 |
What is the 52 Week High and Low of Fulcrum Therapeutics Inc (FULC)?
The 52-week high and low of Fulcrum Therapeutics Inc (FULC) are Rs 15.74 and Rs 2.91 as of 05-Sep-2026.
What is the market cap of Fulcrum Therapeutics Inc (FULC)?
Fulcrum Therapeutics Inc (FULC) has a market capitalisation of $ 294 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Fulcrum Therapeutics Inc (FULC)?
Before investing in Fulcrum Therapeutics Inc (FULC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.